Vaxart, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Vaxart, Inc. (VXRT) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $0.68 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- Vaxart, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $0.68, a 30.77% increase year-over-year.
- Vaxart, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $0.52, a 55.17% decline year-over-year.
- Vaxart, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $1.16, a 48.72% increase year-over-year.
- Vaxart, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $0.78, a 84.58% decline year-over-year.
- Vaxart, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $0.78, a 80.98% decline from fiscal 2022.
- Vaxart, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $4.10, a 42.17% decline from fiscal 2021.
- Vaxart, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2021 was $7.09, a 166.54% increase from fiscal 2020.
- Vaxart, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2020 was $2.66, a 297.01% increase from fiscal 2019.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $0.68 10-Q · filed 2026-08-06 | ||||
| 2026-03-31 | $0.68 S-1 · filed 2026-05-08 | ||||
| 2025-12-31 | $0.53 S-1 · filed 2026-05-08 | ||||
| 2025-09-30 | $0.53 10-Q · filed 2025-11-13 | ||||
| 2025-06-30 | $0.53 10-Q · filed 2025-08-13 | ||||
| 2025-03-31 | $0.52 10-Q · filed 2025-05-13 | ||||
| 2024-12-31 | $1.12 S-1 · filed 2026-05-08 | ||||
| 2024-09-30 | $1.12 10-Q · filed 2024-11-13 | ||||
| 2024-06-30 | $1.12 10-Q · filed 2024-08-08 | ||||
| 2024-03-31 | $1.16 10-Q · filed 2024-05-13 | ||||
| 2023-12-31 | $0.78 10-K · filed 2025-03-20 | ||||
| 2023-09-30 | $0.78 10-Q · filed 2023-11-02 | ||||
| 2023-06-30 | $0.78 10-Q · filed 2023-08-03 | ||||
| 2023-03-31 | $0.78 10-Q · filed 2023-05-04 | ||||
| 2022-12-31 | $4.10 10-K · filed 2024-03-14 | ||||
| 2022-09-30 | $4.38 10-Q · filed 2022-11-09 | ||||
| 2022-06-30 | $4.49 10-Q · filed 2022-08-08 | ||||
| 2022-03-31 | $5.06 10-Q · filed 2022-05-09 | ||||
| 2021-12-31 | $7.09 10-K · filed 2023-03-15 | ||||
| 2021-09-30 | $7.24 10-Q · filed 2021-11-04 | ||||
| 2021-06-30 | $6.52 10-Q · filed 2021-08-05 | ||||
| 2021-03-31 | $6.27 10-Q · filed 2021-05-06 | ||||
| 2020-12-31 | $2.66 10-K · filed 2022-02-24 | ||||
| 2020-09-30 | $2.10 10-Q · filed 2020-11-12 | ||||
| 2020-06-30 | $2.04 10-Q · filed 2020-08-06 | ||||
| 2020-03-24 | $1.70 10-K · filed 2021-02-25 | ||||
| 2019-12-31 | $0.67 10-K · filed 2022-02-24 | ||||
| 2019-09-30 | $0.76 10-Q · filed 2019-11-12 | ||||
| 2019-06-30 | $0.76 10-Q · filed 2019-08-08 | ||||
| 2018-12-31 | $5.17 10-K · filed 2021-02-25 | ||||
| 2018-09-30 | $5.17 10-Q · filed 2018-11-13 | ||||
| 2018-06-30 | $5.17 10-Q · filed 2018-08-10 | ||||
| 2017-12-31 | $4.07 10-K · filed 2019-02-06 | ||||
| 2017-06-30 | $0.90 10-K · filed 2017-09-01 | ||||
| 2017-03-31 | $1.02 10-Q · filed 2017-05-08 | ||||
| 2016-09-30 | $1.33 10-Q · filed 2016-11-08 | ||||
| 2016-06-30 | $2.17 10-K · filed 2017-09-01 | ||||
| 2015-09-30 | $2.45 10-Q · filed 2015-11-06 | ||||
| 2015-06-30 | $2.42 10-K · filed 2016-09-13 | ||||
| 2015-03-31 | $2.44 10-Q · filed 2015-05-08 | ||||
| 2014-12-31 | $2.44 10-Q · filed 2015-02-06 | ||||
| 2014-09-30 | $2.39 10-Q · filed 2014-11-07 | ||||
| 2014-06-30 | $3.95 10-K · filed 2014-09-30 | ||||
| 2014-03-31 | $4.36 10-Q · filed 2014-05-12 | ||||
| 2013-12-31 | $4.15 10-Q · filed 2014-02-10 | ||||
| 2012-09-30 | $1.89 10-Q · filed 2012-11-08 | ||||
| 2012-06-30 | $1.89 10-Q · filed 2012-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |